Analysis
Tunisie
Racine
Analysis
Tunisie
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur le cobalt au Maghreb

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Le cluster Hodgkin Disease (drug therapy) - Risk Factors

Terms

2Hodgkin Disease (drug therapy)
2Risk Factors
2Antineoplastic Combined Chemotherapy Protocols (adverse effects)
4Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
4Child
4Adolescent
3Tunisia (epidemiology)
3Bleomycin (administration & dosage)

Associations

Freq.WeightAssociation
21.000Hodgkin Disease (drug therapy) - Risk Factors
21.000Antineoplastic Combined Chemotherapy Protocols (adverse effects) - Risk Factors
21.000Antineoplastic Combined Chemotherapy Protocols (adverse effects) - Hodgkin Disease (drug therapy)
20.816Risk Factors - Tunisia (epidemiology)
41.000Antineoplastic Combined Chemotherapy Protocols (therapeutic use) - Child
41.000Adolescent - Child
41.000Adolescent - Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
30.866Child - Tunisia (epidemiology)
30.866Bleomycin (administration & dosage) - Child
30.866Antineoplastic Combined Chemotherapy Protocols (therapeutic use) - Tunisia (epidemiology)
30.866Antineoplastic Combined Chemotherapy Protocols (therapeutic use) - Bleomycin (administration & dosage)
30.866Adolescent - Tunisia (epidemiology)
30.866Adolescent - Bleomycin (administration & dosage)
20.816Hodgkin Disease (drug therapy) - Tunisia (epidemiology)
20.816Antineoplastic Combined Chemotherapy Protocols (adverse effects) - Tunisia (epidemiology)
20.707Child - Risk Factors
20.707Child - Hodgkin Disease (drug therapy)
20.707Antineoplastic Combined Chemotherapy Protocols (therapeutic use) - Risk Factors
20.707Antineoplastic Combined Chemotherapy Protocols (therapeutic use) - Hodgkin Disease (drug therapy)
20.707Antineoplastic Combined Chemotherapy Protocols (adverse effects) - Child
20.707Antineoplastic Combined Chemotherapy Protocols (adverse effects) - Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
20.667Bleomycin (administration & dosage) - Tunisia (epidemiology)
Documents par ordre de pertinence
000167 (2003) L. Kochbati [Tunisie] ; H. Boussen ; F. Benna ; Z. Belhaj Ali ; A. Gammoudi ; N. Bouaouina ; M. Besbes ; L. Ghilen ; K. Rahal ; M. Maalej[Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].
000139 (2007) J. Ben Hassouna [Tunisie] ; M. Slimène ; H. Boussen ; H. Bouzaiene ; F. Khomsi ; R. Chargui ; L. Kochbati ; M H Mtaallah ; A. Gamoudi ; F. Benna ; M. Hechiche ; K. Rahal[Secondary breast cancer after treatment for Hodgkin's disease. About seven cases].
000079 (2011) H. Ben Salah [Tunisie] ; M. Bahri ; H. Turki ; M. Abdelmoula ; M. Frikha ; J. Daoud[Radiotherapy for cutaneous cancers with xeroderma pigmentosum].
000099 (2010) M. Frikha [Tunisie] ; N. Toumi ; L. Ghorbel ; H. Ben Salah ; A. Khabir ; H. Karray ; R. Gargouri ; T. Boudawara ; A. Ghorbel ; J. Daoud[Pediatric nasopharyngeal carcinoma: Anatomoclinic aspects, therapeutic results and evolutive particularities].
Wicri

This area was generated with Dilib version V0.6.32.
Data generation: Tue Nov 14 12:56:51 2017. Site generation: Mon Feb 12 07:59:49 2024